NCT06593210View on ClinicalTrials.gov

RSV Vaccine in Transplant Recipients

PHASE3RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

February 28, 2026

Conditions
Vaccine Response ImpairedRespiratory Syncytial Virus InfectionsImmune Suppression
Interventions
BIOLOGICAL

Adjuvant, non-live RSV vaccine

One dose of arexvy vaccine to transplant recipients.

Trial Locations (1)

Unknown

RECRUITING

University Health Network, Toronto

All Listed Sponsors
collaborator

The PSI Foundation, Ontario

UNKNOWN

collaborator

University of British Columbia

OTHER

lead

University Health Network, Toronto

OTHER